Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × UNKNOWN × Pemetrexed × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

INDUSTRY 56 OTHER 27 NIH 4 UNKNOWN 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Squamous Cell 1 Adenocarcinoma 1

Interventions

S 1 (combination) 2 Paclitaxel 2 Oxaliplatin 2 Irinotecan 2 Cisplatin 2 Capecitabine 2 titanium silicide 1 anlotinib 1 Radiation 1 Pemetrexed 1 Lenalidomide 1 HMPL-013 1 Gemcitabine 1 Clinical Trials, Phase II as Topic 1 Clinical Trials, Phase I as Topic 1 Carboplatin 1 Bevacizumab 1 Bendamustine Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03636685 2018-08-17

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

ChineseAMS

Phase 1/2 Unknown

Adenocarcinoma, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡